Antidiabetic Drugs for Steatotic Liver Disease

NCT03646292 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

51

Enrollment

OTHER

Sponsor class

Conditions

MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Type 2 Diabetes
Digestive System Disease
Liver Diseases
Fatty Liver
Metabolic Dysfunction-Associated Steatotic Liver Disease
Non-Alcoholic Fatty Liver Disease
Hypoglycemic Agents
Physiological Effects of Drugs
Sodium-Glucose Cotransporter 2 Inhibitors
Pioglitazone
Molecular Mechanisms of Pharmacological Action
Empagliflozin
Thiazolidinediones

Interventions

DRUG: Pioglitazone
DRUG: Empagliflozin
DRUG: Combination of pioglitazone and empagliflozin

Sponsor

Yonsei University